Mirtazapine: Only for depression?

Acta Neuropsychiatrica

Volumn 18, Issue 3-4, 2006, Pages 130-143

  San, Luis ^a   Arranz, Belen ^a  

^a Hospital de San Rafael   (Spain)

Author keywords

Case reports; Controlled trials; Mirtazapine; Open label trials; Randomized

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; APPETITE STIMULANT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CORTICOSTEROID; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MEDROXYPROGESTERONE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AKATHISIA; ALCOHOL ABUSE; ALCOHOLISM; CANCER PAIN; CLINICAL TRIAL; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSTHYMIA; EMBASE; ESTROGEN THERAPY; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVOLUTIONAL DEPRESSION; MAJOR DEPRESSION; MEDLINE; NETHERLANDS; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCINFO; REVIEW; SCHIZOPHRENIA; SCISEARCH; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOCIAL PHOBIA; TENSION HEADACHE; XEROSTOMIA;

EID: 33748965573     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2006.00143.x     Document Type: Review

References (90)

1. SCHATZBERG AF. New indications for antidepressants. J Clin Psychiatry 2000;61(Suppl. 11):9-17.
2. POMERANTZ JM, FINKELSTEIN SN, BERNDT ER et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004;65:395-404.
3. NUTT DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry 1999;60(Suppl. 17):23-27.
4. NINAN PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999;60(Suppl. 22):12-17.
5. FAWCETT J, BARKIN RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:123-127.
6. GORMAN JM, KENT JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 1999;60(Suppl. 4):33-38.
7. CARPENTER LL, LEON Z, YASMIN S et al. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999;11:81-86.
8. BOSHUISEN ML, SLAAP BR, VESTER-BLOCKLAND ED, DEN BOER JA. The effect of mirtazapine in panic disorder: an open label pilot study with single-blind placebo run-in period. Int Clin Psychopharmacol 2001;16:363-368.
9. CARLI V, SARCHAIPONE M. Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry 2002;59:661.
10. SARCHIAPONE M, AMORE M, DE RISIO S et al. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003;18:35-38.
11. MONTAÑES-RADA F, DE LUCAS-TARACENA MT, SÁNCHEZ-ROMERO S. Mirtazapine versus paroxetine in panic disorder: an open study. Int J Psychiatry Clin Practice 2005;9:87-93.
12. RIBEIRO L, BUSNELLO JV, KAUER-SANT'ANNA M et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001;34:1003-1007.
13. KESSLER RC, SONNEGA A, BROMET E, HUGHES M, NELSON CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:1048-1060.
14. CONNOR KM, DAVIDSON JRT. The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums; Int J Neuropsych Med 1998;3(Suppl. 2):42-51.
15. CONNOR KM, DAVIDSON JRT, WEISLER RH, AHEAM E. A pilot study of mirtazapine in posttraumatic stress disorder. Int Clin Psychopharmacolol 1999;14:29-31.
16. BAHK W-M, PAE C-U, TSOH J et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol Clin Exp 2002;17:341-344.
17. CHUNG MY, MIN KH, JUN YJ, KIM SS, KIM WC, JUN EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004;19:489-494.
18. DAVIDSON JRT, WEISLER RH, BUTTERFIELD MI et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53:188-191.
19. GOODNICK PJ, PUIG A, DEVANE CL, FREUND BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999;60:446-448.
20. GAMBI F, DE BERARDIS D, CAMPANELLA D et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005;19:483-487.
21. VAN VEEN JF, VAN VLIET IM, WESTENBERG HGM. Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol 2002;17:315-317.
22. MUEHLBACHER M, NICKEL MK, NICKEL C et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25:580-583.
23. KORAN LM, QUIRK T, LORBERBAUM JP, ELLIOT M. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:537-539.
24. KORAN LM, GAMEL NN, CHOUNG HW, SMITH EH, ABOUJAOUDE EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005;66:515-520.
25. PALLANTI S, QUERCIOLI L, BRUSCOLI M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004;65:1394-1399.
26. MONTGOMERY SA, MONTGOMERY D, EVANS R. Pharmacological differences between brief andmajor depressions. Eur Neuropsychopharmacol 1993;3(Suppl. 3):214-215.
27. STAMENKOVIC M, PEZAWAS L, DE ZWAAN M. Mirtazapine in recurrent brief depression. Int Clin Psychopharmacol 1998;13:39-40.
28. DUNNER DL, HENDRICKSON HE, BEA C, BUDECH CB, O'CONNOR E. Dysthymic disorder: treatment with mirtazapine. Depress Anxiety 1999;10:68-72.
29. JOFFE H, GRONINGER H, SOARES CN, NONACS R, COHEN LS. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gend Based Med 2001;10:999-1004.
30. NIEDERMAIER N, BOHRER E, SCHULTE K, SCHLATTMANN P, HEUSER I. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 2004;65:1619-1623.
31. ELLIOT AJ, ROY-BYRNE PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000;20:265-267.
32. SERRA M, PLANA MT, BLANCH J, DE PABLO J, GASTÓ C. Mirtazapina en el tratamiento de la depression en pacientes VIH positivos. Rev Psiquiatría Fac Med Barna 2004;31:264-271.
33. GARDNER ME, MALONE DC, SEY M, BABINGTON MA. Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc 2004;5:101-106.
34. CRONE CC, GABRIEL GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2004;43:361-394.
35. KIM J, PHONGSAMRAN P, PARK S. Use of antidepressant drugs in transplant patients. Prog Transplant 2004;14:98-104.
36. FETTER JC. Mirtazapine for MDMA-induced depression. Am J Addict 2005;14:300-301.
37. COLOMBO B, ANNOVAZZI PO, COMI G. Therapy of primary headaches: the role of antidepressants. Neurol Sci 2004;25(Suppl. 3):S171-S175.
38. MILLER A, RABE-JABLONSKA J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain - a review. Psychiatr Pol 2005;39:21-32.
39. FREYNHAGEN R, MUTH-SELBACH U, LIPFERT P et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006;22:257-264.
40. NUTT D, LAW J. Treatment of cluster headache with mirtazapine. Headache 1999;39:586-587.
41. BRANNON GE, ROLLAND PD, GARY JM. Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics 2000;41:153-154.
42. LEVY E, MARGOLESE HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol 2003;18:301-303.
43. MARTÍN-ARAGUZ A, BUSTAMANTE-MARTÍNEZ C, DE PEDRO-PIJOÁN JM. Treatment of chronic tension-type headache with mirtazapine and amitryptyline. Rev Neurol 2003;37:101-105.
44. BENDTSEN L, JENSEN R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004;62:1706-1711.
45. THEOBALD DE, KIRSH KL, HOLTSCLAW E, DONAGHY K, PASSIK SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002;23:442-447.
46. VAN GOOL AR, BANNINK M, STRONKS DL, VOS MS. Mirtazapine in cancer patients. J Pain Symptom Manage 2003;25:7-8.
47. DAVIS MP, KHAWAM E, POZUELO L, LAGMAN R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. Expert Rev Anticancer Ther 2002;2:365-376.
48. SAMBORSKI W, LEZANSKA-SZPERA M, RYBAKOWSKI JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004;37:168-170.
49. LIAPPAS J, PAPARRIGOPOULOS T, TZAVELLAS E, CHRISTODOULOU G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord 2003;76:279-284.
50. LIAPPAS J, PAPARRIGOPOULOS T, MALITAS P, TZAVELLAS E, CHRISTODOULU G. Mirtazapine improves alcohol detoxification. J Psychopharmacol 2004;18:88-93.
51. CROCKFORD DN, WHITE WD. Mirtazapine for alcohol dependence: a case report. J Clin Psychiatry 2005;66:540.
52. LIAPPAS J, PAPARRIGOPOULOS T, TZAVELLAS E, RABAVILAS A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:55-60.
53. KONGSAKON R, PAPADOPOULOS KI, SAGUANSIRITHAM R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 2005;20:253-256.
54. RAMIREZ N, ARRANZ B, SANCHEZ JM, CENTENO M, SAN L. Depression in schizophrenia, can it be treated? A review of the evidence. Curr Psychiatr Rev 2006;2:371-379.
55. BERK M, ICHIM C, BROOK S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16:87-92.
56. ZOCCALI R, MUSCATELLO MR, CEDRO C et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19:71-76.
57. ZOCCALI R, MUSCATELLO MR, LA TORRE D et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003;48:411-414.
58. POYUROVSKY M, WEIZMAN A. Mirtazapine for neuroleptics-induced akathisia. Am J Psychiatry 2001;158:819.
59. RANJAN S. Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006;40:771-774.
60. POYUROVSKY M, EPSHTEIN S, FUCHS C, SCHNEIDMAN M, WEIZMAN R, WEIZMAN A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003;23:305-308.
61. WALDINGER MD, BERENDSEN HH, SCHWEITZER DH. Treatment of hot flashes with mirtazapine: four case reports. Maturitas 2000;36:165-168.
62. PEREZ DG, LOPRINZI CL, BARTON DL et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004;2:50-56.
63. THASE ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl. 17):28-31.
64. THASE ME. Treatment issues related to sleep and depression. J Clin Psychiatry 2000;61 (Suppl. 11):46-50.
65. WILSON S, ARGYROPOULOS S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65:927-947.
66. RUIGT GS, KEMP B, GROENHOUT CM, KAMPHUISEN HA. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-554.
67. WHEATLEY DP, VAN MOFFAERT M, TIMMERMAN L, KREMER CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-312.
68. LEINONEN E, SKARSTEIN J, BEHNKE K, AGREN H, HELSDINGEN JT. Efficacy and tolerability of mirtazapine versus citalopram: a double blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999;14:329-337.
69. BENKERT O, SZEGEDI A, KOHNEN R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
70. THASE ME, NIERENBERG AA, KELLER MB, PANAGIDES J, Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001;62:782-788.
71. WINOKUR A, DEMARTINIS NA, MCNALLY DP, GARY EM, CORMIER JL, GARY KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64:1224-1229.
72. SCHITTECATTE M, DUMONT F, MACHOWSKI R, CORNIL C, LAVERGNE F, WILMOTTE J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201.
73. GUELFI JD, ANSSEAU M, TIMMERMAN L, KORSGAARD S, Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalised severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21:425-431.
74. WINOKUR A, SATEIA MJ, HAYES JB. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000;48:75-78.
75. HIRSCHFIELD RMA. Management of sexual side effects of antidepressant therapy. J Clin Psychiatry 1999;60(Suppl. 14):27-30.
76. HIRSCHFELD RMA. Care of the sexually active depressed patient. J Clin Psychiatry 1999;60(Suppl. 17):32-35.
77. FAWCETT J, BARKIN RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285.
78. BARKIN RL, CHOR PN, BRAUN BG, SCHWER WA. A trilogy case review highlighting the clinical and pharmacologic applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction. Prim Care Companion J Clin Psychiatry 1999;1:142-145.
79. KOUTOUVIDIS N, PRATIKAKIS M, FOTIADOU A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol 1999;14:253-255.
80. GELENBERG AJ, MCGAHUEY C, LAUKES C et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000;61:356-360.
81. FARAH A. Lack of sexual adverse effects with mirtazapine. Am J Health Syst Pharm 1998;55:2195-2196.
82. FARAH A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment. J Clin Psychiatry 1999;60:260-261.
83. BOYARSKY BK, HAQUE W, ROULEAU MR, HIRSCHFELD RM. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999;9:175-179.
84. CLAYTON AH, PRADKO JF, CROFT HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366.
85. MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl. 3):10-21.
86. PAHWA R, LYONS KE. Mirtazapine in essential tremor: a double-blind, placebo controlled pilot study. Mov Disord 2003;18:584-587.
87. DAVIS MP, FRANDSEN JL, WALSH D, ANDRESEN S, TAYLOR S. Mirtazapine for pruritus. J Pain Symptom Manage 2003;25:288-291.
88. BIGATA X, SAIS G, SOLER F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol 2005;53:916-917.
89. KIM SW, SHIN IS, KIM JM, LIM SY, YANG SJ, YOON JS. Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuropharmacol 2005;28:249-251.
90. GUCLU S, GOL M, DOGAN E, SAYGILI U. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005;272:298-300.